Diabetes and related complications {#s1}
==================================

Diabetes mellitus includes a series of metabolic disorders due to the lack or diminished effectiveness of insulin secretion (Chiang et al., [@B17]; American Diabetes Association, [@B6]). Diabetes can be classified based on its pathogenesis in two distinct classes: the type 1 diabetes, also known as juvenile diabetes, and type 2 diabetes, also known as adult-type diabetes. Both types of diabetes are preceded by a period during which it is observed an impaired glucose homeostasis (Roden, [@B53]). Prediabetes is an asymptomatic medical condition that does not cause any functional impairment; patients who are in this situation may evolve toward diabetes in varying degrees on the basis of genetic and environmental factors. Prediabetic patients are at an increased risk of developing Type 2 Diabetes Mellitus (Allende-Vigo, [@B5]). The World Health Organization estimated that 9% of adults worldwide suffer from diabetes, and the total number is predicted to increase by over 50% over the next 20 years (Fonseca, [@B20]). The epidemiology of diabetes includes population growth, urbanization, aging, ethnicity, increased prevalence of obesity, hypertension, and increased sedentary (Krijnen et al., [@B33]). Dysfunction of beta cell lead to altered insulin production and secretion resulting in hyperglycemia and glucose intolerance manifesting to diabetes mellitus. Diabetes is associated with premature death, coronary artery disease, and myocardial infarction, stroke, peripheral vascular disease and limb amputation, blindness, kidney failure, and the requirement for dialysis, as well as in several infrequently occurring complications. Diabetic complications are classified into two main groups: the acute and the chronic complications. The former includes diabetic keto-acidosis which is generally encountered in type 1 and nonketotic hyperosmolar syndrome which is common in type 2 diabetes mellitus. The other types of diabetic complications refer to the chronic ones, which may involve several organs and representing the major cause of morbidity and mortality in patients with diabetes mellitus (Tripathi and Srivastava, [@B70]). The chronic complications of diabetes have been classified as either vascular or non-vascular. The vascular diabetic complications are sub-classified into microvascular including damage to kidneys, eyes, and nerves. The latter leads to diabetic foot ulcer developing into gangrene and amputation. Diabetic ischemic ulcer is an intractable diabetic complication. Recently, transplantation of stem cells is considered as a possible new therapeutic strategy for the treatment of diabetic ulcers. Macrovascular complications are due to damage of the larger blood vessels through a process known as "atherosclerosis," leading to a narrowing of the vessel lumen and consequent reduction of blood supply in the serving district. Non-vascular complications include gastroporesis and diarrhea, uropathy, or sexual dysfunction, and skin manifestations, gum infection, and complications of eye like cataract and glaucoma (Tripathi and Srivastava, [@B70]; Cade, [@B11]). The treatment of diabetes mellitus includes diet (Li Volti et al., [@B38]; Marrazzo et al., [@B42]), therapy with insulin and/or oral hypoglycemic agents and pancreas transplantation or pancreatic islets (Logdberg et al., [@B39]). However, because of the limited availability of donor organs, recent studies have focused on the possibility of using stem cells for the treatment of DM (Li and Ikehara, [@B36]).

Health impact of adult stem cells {#s2}
=================================

Multipotent stem cells, which have gradually turned out to play a key role in regenerative medicine therapies, can be retrieved from adult tissue, and bone marrow (BM) represents an important source for these cells. The stem cells derived from BM, as well as umbilical cord blood or the placenta, are all indicated as adult stem cells. The BM mainly contains two types of stem cells: hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). MSCs have been described for the first time by Friedenstein et al. as very similar to fibroblast cells capable of differentiating into cells of the bone tissue (Friedenstein et al., [@B22]; Hematti, [@B26]). The fate of a stem cell is determined by its niche, or local micro-environment. Stem cells actively contribute to their environment by secreting cytokines, growth factors and extracellular matrix molecules that act paracrinally and autocrinally. MSCs are considered a critical component of the bone marrow micro-environment, and directly contribute to the development of hematopoietic stem cells, readily distinguishable from MSCs by their cell surface markers. MSCs are considered multipotent stem cells that are capable of self-renewing and differentiating into different functional cell types. The ease of isolation, the high migratory capacity, the relatively high expansion rates, and the ability to avoid the allogeneic responses after transplantation (Sekiya et al., [@B59]; Chen et al., [@B16]; Fouillard et al., [@B21]), make them attractive candidates in regenerative medicine (Pacini, [@B49]). Recent findings show that MSCs participate in tissue repair processes through various mechanisms including the migration into the damaged tissue (Sordi et al., [@B60]) and the release of paracrine factors such as cytokines and other trophic factors (Caplan and Dennis, [@B14]; Salomone et al., [@B56]).

To this regard, recent animal studies and clinical trials have shown that MSCs are effective in acute myocardial infarction and chronic heart failure and this effect is related to the release of paracrine signals involved in the differentiation of cardiomyocytes, smooth muscle cell, vascular endothelial cells, and stimulating endogenous repair (Boyle et al., [@B9]). Improvements in myocardial function following stem cells transplantation have been attributed to stem cells differentiation into cardiomyocytes within host myocardium. However, it has been demonstrated that few exogenous stem cells actually engraft and differentiate into cardiomyocyte lineage. Several studies showed that BM-MSCs secrete cytoprotective molecules that reduce apoptosis and necrosis (Baraniak and McDevitt, [@B7]). Furthermore, it has been demonstrated that resident cardiac progenitor cells are abundantly present within the myocardium in niches preferentially located in the atria and apex and in the ventricle and effectively preserve the integrity of the tissue. Cardiac progenitor cells appear to migrate and accumulate within ischemic and scarred myocardium in order to evoke cardiac regeneration. It has been shown that MSCs can secrete a number of chemotactic factors that may contribute to the activation and migration of cardiac progenitor cells toward areas of injury. Although, it is widely accepted that MSCs functionality is highly affected by sex, age, disease, and the pharmacological treatment of donors, controversies about influence of tissue origins are still debated. These differences may be related to the influence of a modified local environment (niche) present in a different site of the body.

The local microenvironment protects the stem cells and modify their biological behavior. In that regard, the identification and characterization of the stem cells niches has been particularly complex from the time that stem cells are poorly present, and in some cases are devoid of cellular markers that can allow their secure identification. Recently studies described that in the bone marrow, besides MSCs and HSCs, there are different progenitor cells including the endothelial progenitor cells (EPCs) and the mesodermal progenitor cells (MPCs). Pacini at al. isolated MPCs from culture of human bone marrow-derived cells and observed that MPCs differ from MSCs in terms of their morphology and in terms of their quiescent status (Pacini et al., [@B50]). MPCs have been proven to be capable of generating CFU-F and of differentiating into mesodermal lineages (adipocytes, chondrocytes, and osteoblasts), in the presence of appropriate stimuli, (Pittenger et al., [@B51]) and through the commitment into an intermediate cell population which is considered "early MSCs." Furthermore, MPCs may differentiate into endothelial cells when cultured in an appropriate VEGF-containing medium similar to those used in the differentiation of embryonic cells (Trombi et al., [@B71]). Circulating EPCs are regarded as the cells expressing both stem cell markers and endothelial cell markers. EPCs circulate in the blood and appear to home preferentially to sites of vascular or tissue injury, contributing significantly to both reendothelialization and angiogenesis. Many evidences suggest that BM-derived EPCs have the potential to promote angiogenesis in the postnatal period, thus providing a good rationale for their use in clinical practice for the treatment of cardiovascular diseases. It has been reported that transplantation of EPCs derived from healthy human peripheral blood, significantly increased vascularization, and improved the survival rate after acute liver injury in mice (Taniguchi et al., [@B66]). Thus, therapeutic approaches using culture-expanded adult stem cells, including progenitor stem cells, could successfully promote regeneration of damaged tissues in cardiovascular diseases.

In addition to these properties, that support the use of stem cells in regenerative medicine, it must be added the capability of this cell type to modulate the T cell response and/or to provide a microenvironment with immunosuppression capacity. The latter ability of MSCs has generated considerable interest in the scientific community since this specific feature could be exploited in the downregulation of the immune response that occurs in graft-vs.-host-disease and autoimmune diseases such as multiple sclerosis, type 1 diabetes and rheumatoid arthritis (Glenn and Whartenby, [@B23]). During an immune response, MSCs are known to communicate with the inflammatory micro-environment. MSCs express a large number of surface molecules including members of the integrin family and adhesion molecules that promote cellular interactions via receptors binding on immune cells (Najar et al., [@B46]).

The broad applicability of MSCs in a plethora of metabolic and degenerative disease models is subsequent partially to the ability of MSCs to modulate several cellular component of the innate and adaptive immune system. These features have attracted significant interest in the field of solid organ transplants and some studies have been done to evaluate the effect of the infusion of MSCs simultaneously to organ transplantation in patients treated with standard immunosuppression protocol. MSCs cotransplantation prolonged islet graft survival in all recipients when they also were treated with CTLA4Ig and anti-CD40L (Takahashi et al., [@B65]). In NOD mice, the administration of a single infusion of MSCs was able to prevent the onset of type 1 diabetes and to retard its progression by inhibiting the accumulation of effector T-cells (Madec et al., [@B40]). The immunosuppressive effects of MSCs are induced by the activation of several key enzymes, such as nitric oxide synthase, cyclo oxygenase-2, and Heme Oxygenase (HO)-1 (Hinden et al., [@B27]). Interestingly, human MSCs express HO-1 levels, but HO-1 inhibition significantly reduces the suppressive effects of MSCs, highlighting the key role of HO-1 in the immunosuppression mediated by human MSCs (Chabannes et al., [@B15]).

Biological functions of heme oxygenase {#s3}
======================================

HO exists in two forms, HO-1, the inducible form, and HO-2, the constitutive form. Both isoforms degrade heme into biliverdin with the concurrent release of carbon monoxide (CO) and iron (Abraham et al., [@B1]). In mammals, biliverdin is then reduced by biliverdin reductase to bilirubin (Kapitulnik and Maines, [@B32]). Iron, bilirubin, and CO, the three byproducts of the HO reaction, possess important biological functions. Both bilirubin and biliverdin have good antioxidant activity and may exert protective effects both *in vivo* and *in vitro* under various experimental conditions (Stocker et al., [@B62]; Sacerdoti et al., [@B55]). CO may serve as a second messenger in the central nervous system (Verma et al., [@B75]), it inhibits endothelial cell apoptosis through the activation of p38MAPK (Otterbein and Choi, [@B48]; Sacerdoti et al., [@B55]) and acts as a vasodilator through the stimulation of guanylate cyclase. HO-1 can be induced by many drugs and chemical agents, including statins, aspirin, prostaglandins, eicosanoids, and metals (Marrazzo et al., [@B43]; Tibullo et al., [@B69]; Abraham et al., [@B1]). Furthermore, several natural antioxidant compounds contained in foods and plants have been demonstrated to regulate HO-1 levels in various cellular models (Acquaviva et al., [@B4]; Vanella et al., [@B73], [@B74]). HO-2 contributes to basal physiological functions while HO-1 represents the major cytoprotective moiety of the HO system, by scavenging ROS and preventing apoptosis (Novo et al., [@B47]; Burgess et al., [@B10]; Tibullo et al., [@B69]). HO may represent a beneficial target to limit the pathogenesis of obesity, diabetes and their complications. It is noteworthy that, an excessive increase in visceral fat is associated with insulin resistance, diabetes and hypertension. Induction of HO-1 in diabetes has been reported to restore the functionality of several mitochondrial carriers, increase Akt phosphorylation and to improve renal function (Di Noia et al., [@B19]). In addition, HO-1 upregulation leads to a decrease in ROS and LDL levels in many diabetes models. Targeting HO-1 or the products of heme degradation stems from the finding that over-expression of HO-1 increases insulin sensitivity, decreases body weight, and reduces proinflammatory adipokines including TNF-α, IL-6, and MCP-1 (Marino et al., [@B41]). A decrease in heme levels, consequent to HO-1 activation, limits heme availability for the maturation of gp91phox subunit and assembly of the functional NADPH oxidase which represents the major source of the superoxide anion (Taille et al., [@B64]).

Therapeutic potential of HO on stem cells transplantation {#s4}
=========================================================

MSCs could be exploited for the delivery of specific genes for therapeutic purposes. In this regard, some studies suggest that genetic modification of MSCs prior to transplantation can lead to increased survival, improved engraftment and improved cardiac outcome in models of myocardial infarction (Gnecchi et al., [@B24]; Wang et al., [@B77]). Cai at al. demonstrated that pretreatment of human cardiac stem cells with cobalt protoporphyrin (CoPP), an HO-1 inducer, enhanced cells survival, and resulted in great improvement in left ventricular remodeling and in indices of cardiac function after infarction (Cai et al., [@B12]). In addition to that, previous studies suggested that CoPP increases the survival of cardiomyocytes and restores contractility to adult cardiomyocytes grafts implanted *in vivo* as well as protects the heart from ischemic damage in both normal and diabetes rats (Cao et al., [@B13]). The use of stem cells as a potential approach to treat diabetes may also offer the possibility to selectively deliver the expression of HO-1 in a cell and organ specific manner without the need of a viral vector or specific promoters. In fact, HO-1 induction may be easily achieved by pharmacological means prior stem cell transplantation in the patients by several agents. In particular, various chemical compounds have been used both *in vivo* and *in vitro* to induce HO-1 such as SnCl~2~ or CoPP. However, there could be some limitations on the possible use of these compounds into a clinical setting because of the metal toxicity. Noteworthy, previous reports showed that natural polyphenols may be used as good inducers of HO-1 because of their ability of activating the Nrf2/Keap1 pathway and may represent a good and safe strategy to induce HO-1 prior to stem cell transplant (Scapagnini et al., [@B58]; Marrazzo et al., [@B43]; Barbagallo et al., [@B8]).

Despite the widespread use of hypoglycemic agents, morbidity and mortality caused by type 1 diabetes mellitus represent a significant burden for society, both in terms of human suffering and cost (Logdberg et al., [@B39]). Transplantation of pancreatic islets is an important approach to the treatment of diabetes type 1, but after the transplant procedure, cells frequently undergo apoptosis causing a dysfunction of the islets. It has been demonstrated, *in vivo*, that treatment of the mouse donor with carbon monoxide, a reaction product of HO-1, suppresses the proinflammatory response, characterized by an increase of TNF-α, IL-1β, and MCP-1, in the islets after transplantation (Wang et al., [@B76]). Ikehara\'s group described the use of stem cells for the treatment of both type 1 and type 2 diabetes (Ikehara, [@B29]) by a reduction in the development of hyperglycemia and hyperinsulinemia in diabetic mice (Than et al., [@B68]; Abraham et al., [@B3]). Chronic hyperglycemia leads to a reduction of the expression of HO-1 and the total enzyme activity, resulting in increased levels of superoxide anion, and cell death (Abraham et al., [@B2]). Oxidative stress has been shown to play a key role in the pathogenesis of insulin resistance in type 2 diabetes and of cardiovascular complications (Wellen and Hotamisligil, [@B78]; Ruotsalainen et al., [@B54]). Previous report demonstrated that the transplantation of bone marrow mesenchymal stem cells (BMMSCs) via intra bone marrow-bone marrow transplantation (IBM-BMT) in conjunction with the induction of HO-1 ameliorate type 2 diabetes mellitus (Li and Ikehara, [@B36]).

Previous studies showed that transplantation of bone marrow stem cells, including MSCs, but not limited to CD34^+^ stem cells, into type 2 diabetic mice restored insulin sensitivity and improved glucose tolerance (Abraham et al., [@B3]). Pretreatment with a HO-1 inducer followed by the IBM-BMT offers great improvement in diabetes, glucose tolerance, and oxidative stress. The mechanism by which HO-1 improves the effectiveness of IBM-BMT is due to a decrease in superoxide levels, which causes impairment in MSCs function and release of crucial cytokines. Hyperglycemia-induced reactive oxygen species accumulation has been postulated to be a central mediator of diabetes mellitus--induced EPCs dysfunction (Sambuceti et al., [@B57]). Several studies demonstrated that EPCs represent an important contributor to neovascularization, through the secretion of paracrine angiogenic factors (Urbich et al., [@B72]). Reduced number and function of EPCs are causally associated with diabetes mellitus--induced impairment in vasculogenesis (Tepper et al., [@B67]; Sorrentino et al., [@B61]). A diminished HO-1/AMPK signaling cascade in EPCs may account in part for impaired reendothelialization in diabetes mellitus (Li et al., [@B34]). EPCs isolated from diabetic mice and transplanted into injured arteries of recipient diabetic mice, didn\'t show a significant efficacy, whereas the attachment capacity of EPCs isolated from diabetic transgenic mice, over expressing AMPK-HO-1 levels, was comparable to that of EPCs from healthy mice (Li et al., [@B34]). Treatment of transgenic diabetic mice with a specific HO-1 inhibitor (ZnPPIX) abolished the HO-1 mediated effects, providing a direct evidence that HO-1 upregulation restores the function of damaged EPCs (Li et al., [@B34]). Experiments *in vitro* revealed that HO-1 is necessary for proper activity of BM-derived stem cells (BMDCs). Indeed, HO-1-deficient BMDCs are less viable when exposed to oxidants and display a weaker proliferation and migration capacity (Grochot-Przeczek et al., [@B25]). Similar effects were observed in murine mature or progenitor endothelial cells (Jozkowicz et al., [@B31]; Deshane et al., [@B18]) and in human endothelium with less active variants of Hmox1 promoter (Taha et al., [@B63]). In particular, it has been also demonstrated a weaker angiogenic potency of HO-1 −/− BMDCs in capillary sprouting assay, confirming the results obtained earlier in human endothelial cells treated with HO-1 inhibitors or in murine endothelial cells isolated from HO-1 +/+ or HO-1 −/− mice (Grochot-Przeczek et al., [@B25]). People with diabetes may be at increased risk of developing acute renal failure. Furthermore, numerous studies highlighted diabetes as a major risk factor for the development of acute renal injury (AKI) in hospitalized patients (Johnson et al., [@B30]). Several studies have shown that the BMSCs transplantation may play a beneficial role following renal ischemic injury, possibly by the paracrine/autocrine mechanisms, or by trans-differentiation into the local cell types (Morigi et al., [@B45]; Qian et al., [@B52]; Li et al., [@B35]). However, after transplantation into the dysfunctional kidney, BMSCs face a pro-oxidant environment characterized by hypoxia, oxidative stress, and inflammation (Mias et al., [@B44]) that can lead to reduced cell survival and consequently to a decreased therapeutic effect. The oxidative stress leads to stress-induced premature senescence, cell death, and apoptosis of the transplanted BMSCs. Recently, it was reported that over-expression of HO-1, by gene transfection, in BMSCs, was able to improve HO-1-BMSCs survival in the I/R-AKI micro-environment and decrease the levels of MCP-1, TNF-a, and IL-1, leading to a greater improvement of renal function compared to BMSCs treatment alone (Liu et al., [@B37]). Recently, stem cell transplantation has been considered as a new therapeutic strategy for diabetic foot ulcers. Hou\'s group demonstrated that the over-expression of HO-1 in BMSCs promoted angiogenesis and wound healing in diabetic ischemic ulcers (Hou et al., [@B28]). In conclusion, these recent studies demonstrate that induction of HO-1 plays a key role in stem cell survival during transplantation of adult stem cells (Figure [1](#F1){ref-type="fig"}). Thus, HO-1 represents a new target for designing new compounds with clinical application in the treatment of diabetes.

![**Schematic representation demonstrating the role of HO-1 in stem cells transplantation**.](fcell-04-00080-g0001){#F1}
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